Sign In
Buy ABT
$90.51
-0.0200 (-0.0221%)
At Close: Jun 24, 2026
Abbott Labs CEO on Q2 earnings
11:27am, Thursday, 18'th Jul 2024
Abbott Labs CEO Robert Ford joins 'Squawk on the Street' to discuss what's driving the company's double-digit gains in the quarter, his take on the 2024 election, and more.
Compared to Estimates, Abbott (ABT) Q2 Earnings: A Look at Key Metrics
10:36am, Thursday, 18'th Jul 2024
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to W
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
09:45am, Thursday, 18'th Jul 2024
Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.08 per share a year ago.
2 Healthcare Stocks For Your Mid-July 2024 Watchlist
09:38am, Thursday, 18'th Jul 2024
Healthcare stocks to check out in the stock market right now.
Why This Leading Health Stock is a Buy No Matter the Market Move
09:26am, Thursday, 18'th Jul 2024
Abbott Laboratories NYSE: ABT is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It's not always a good bu
Abbott raises annual profit forecast as strong medical device sales power quarterly beat
07:32am, Thursday, 18'th Jul 2024
Abbott Laboratories raised its annual profit forecast on Thursday and beat Wall Street estimates for second-quarter earnings, buoyed by strong sales of its cardiac and diabetes devices.
Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance
07:30am, Thursday, 18'th Jul 2024
Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digi
Don't buy the dip as the summer slump is officially here, says Goldman strategist
06:49am, Thursday, 18'th Jul 2024
A modest bounce for the Nasdaq Composite could be in the making for Thursday, following the worst one-day percentage drop for the tech index, as a recent rotation out of its biggest companies got ampe
2 Dividend Stocks to Buy and Hold Forever
06:01am, Thursday, 18'th Jul 2024
Microsoft and Abbott Laboratories have been leaders in their respective industries for decades. Both companies have important growth opportunities and impressive innovative abilities.
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
03:05am, Thursday, 18'th Jul 2024
Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.
Down 7% This Year Will Abbott Stock See Higher Levels Post Q2 Results?
12:45pm, Wednesday, 17'th Jul 2024
Abbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly alignin
Utility says Houston power will be mostly restored by Wednesday, as Abbott threatens punishment
08:24pm, Monday, 15'th Jul 2024
AUSTIN, Texs — The majority of Houston outages that followed Hurricane Beryl should be fixed within the next two days, the city's main utility company said Monday as Texas Gov. Greg Abbott threatene
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
11:00am, Saturday, 13'th Jul 2024
Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such a
Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release
11:30am, Thursday, 11'th Jul 2024
Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
10:32am, Thursday, 11'th Jul 2024
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
